1. ALLA AKTIER
  2. NYHETER
  3. ABLIVA

Abliva

Nyheter Abliva Nyheter alla bolag

Abliva AB Interim Report January – June 2023

REG

The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354

Second quarter summary

Important events second quarter (Apr – Jun 2023)

  • The first patient was dosed in Abliva’s global, potentially registrational, clinical Phase 2 study with lead drug candidate KL1333 - the FALCON study.
  • Abliva’s drug candidate NV354 was granted Orphan Drug Designation (ODD) in the U.S. for the treatment of mitochondrial disease.
  • Abliva’s Annual General Meeting was held on May 5. All proposals were passed by the general meeting. For more information, see Abliva’s website www.abliva.com.

Financial information

April-June 2023*

  • Net revenues: SEK 0 (0)
  • Other operating income: SEK 2,711,000 (0)
  • Loss before tax: SEK 21,226,000 (20,535,000)
  • Loss per share before dilution: SEK 0.02 (0.04)
  • Diluted loss per share: SEK 0.02 (0.04)

January-June 2023*

  • Net revenues: SEK 0 (0)
  • Other operating income: SEK 3,766,000 (0)
  • Loss before tax: SEK 37,318,000 (42,564,000)
  • Loss per share before dilution: SEK 0.04 (0.09)
  • Diluted loss per share: SEK 0.04 (0.09)

* APM Alternative performance measures, see definition on page 20.

The complete Interim report is available for download below and through Abliva's website www.abliva.com.

This information is information that Abliva AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 2023-08-18 08:30 CEST.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Abliva AB Interim Report January – June 2023

Datum 2023-08-18, kl 08:30
Källa MFN
Bifogade filer
Abliva AB Interim Report January – June 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!